BETA CELL TECHNOLOGIES
Our vision is to find a cure for type 1 diabetes
Type 1 Diabetes Mellitus (T1D), either as the primary disease or its multi-system complications, is one of the largest burdens on health services globally. It is a serious, life-long autoimmune disease that usually occurs in childhood but can be diagnosed at any age. T1D occurs when the pancreas does not produce enough insulin (a hormone that regulates blood sugar, or glucose), due to the immune system destroying insulin-producing beta cells within the pancreas. T1D is an increasing public health problem, because both the number of cases and the prevalence of the disease have been steadily increasing over the past few decades.
Beta Cell has identified an opportunity to design, develop and implement a novel Intracutaneous Ectopic Pancreas (IEP) to treat T1D on a local, national and global scale. The pioneering treatment consists of seeding human Islets of Langerhans into an integrated Biodegradable Temporising Matrix (NovoSorb®BTM). At this site, the cells survive whilst being nurtured within the highly vascularised and loosely-woven collagen structure which develops inside the NovoSorb®BTM. This is an ideal site for the seeding of human cells to produce ectopic organs in the skin, because establishment of the IEP, monitoring and analysis of structure and function, and complete IEP removal are facilitated. Beta Cell has patents pending in Australia, the United States and Europe.
Beta Cell Technologies and our collaborating partners are delighted to announce the online publication of our pre-clinical studies showing the Biodegradable Temporizing Matrix (BTM, Novosorb) supporting survival of pancreatic islet cells in a completely new intracutaneous transplant site outside of the liver in the American Diabetes Association flagship Journal Diabetes.
A world-first treatment developed here in Adelaide could mean researchers are one step closer to finding a cure for type 1 diabetes. The innovative procedure will see patients produce their own insulin, without the need for daily pumps and injections.
BCT is excited to be partnering with Professor Shane Grey from the Garvan Institute in Sydney to trial A20-modified islets in our exclusive intracutaneous islet transplant site – a novel treatment for type 1 diabetes. This work will follow on from our current first-in-human trial of intracutaneous transplantation of unmodified islets funded by JDRF Australia and JDRF International performed at the Royal Adelaide Hospital.